Well, it's always nice to have someone who has been down the path of a successful regulatory approval post P3 with the FDA. And in this case, as part of the Trofinetide approval. There has to be people still in the Neurology 'department' post-Trump that DeKarske has networked with as part of that role with Acadia and getting Daybue through. Seems like another smart move by Management to me.
NEU Price at posting:
$11.80 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)